辉瑞新型抗菌药物思福诺在华正式获批

Core Insights - Pfizer's new antibacterial drug, Sifonuo® (injection of amikacin and avibactam sodium), has received official approval from the National Medical Products Administration in China [1] Group 1: Product Approval - The drug is approved for the treatment of complex intra-abdominal infections (cIAI) in adults caused by Gram-negative bacteria with limited or no alternative treatment options [1] - It is also indicated for hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) [1]